Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CASI Pharmaceuticals, Inc. - Ordinary Shares (NQ:CASI)

1.910 -0.200 (-9.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
Via ACCESS Newswire
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
Via ACCESS Newswire
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
Via ACCESSWIRE
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
Via ACCESSWIRE
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
Via ACCESSWIRE
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China
LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class... 
From BioInvent International
Via AccessWire
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.